Interferon-beta 1b

( DrugBank: Interferon-beta / KEGG DRUG: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
13	多発性硬化症／視神経脊髄炎	16

13. 多発性硬化症／視神経脊髄炎

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

trials per page:

Showing 1 to 10 of 16 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04356339 (ClinicalTrials.gov)	November 24, 2020	19/4/2020	US PROmyBETAapp2.0: A Study to Learn More About the Medication Usage and Patient Reported Outcomes V ...	US PROmyBETAapp2.0: Ascertaining Medication Usage and Patient-reported Outcomes (PROs) Via the myBET ...	Multiple Sclerosis	Drug: Interferon-beta-1b (BETASERON, BAY 86-5046)	Bayer	NULL	Completed	18 Years	N/A	All	100		United States
2	EUCTR2012-005450-30-AT (EUCTR)	08/01/2014	11/11/2013	Investigation of neutralising antibodies against interferon-betain patients with multiple sclerosis, ...	Anti-Biopharmaceutical Immunization: Prediction and analysis of clinical relevance to minimize the r ...	Development of neutralising antibodies against Interferon-betain the treatment of multiple sclerosis ...	Trade Name: Avonex INN or Proposed INN: Interferon-beta1a Other descriptive name: INTERFERON BETA-1A Tr ...	Medizinische Universität Innsbruck	NULL	Not Recruiting			Female: yes Male: yes	100	Phase 4	Austria;Sweden
3	EUCTR2012-004040-30-AT (EUCTR)	24/05/2013	12/03/2013	Natalizumab de-escalation to interferon-beta-1bin patients withrelapsing-remitting multiple sclerosi ...	Natalizumab de-escalation to interferon-beta-1bin patients withrelapsing-remitting multiple sclerosi ...	relapse-remitting multiple sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: BETAFERON® (interferon beta-1b) Product Name: Betaferon INN or Proposed INN: Betaferon Othe ...	Ospedale Regionale di Lugano	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	72		Austria;Switzerland
4	NCT01701856 (ClinicalTrials.gov)	September 2012	18/9/2012	Natalizumab De-escalation to Interferon-beta-1bin Patients With Relapsing-remitting Multiple Scleros ...	Natalizumab De-escalation to Interferon-beta-1bin Patients With Relapsing-remitting Multiple Scleros ...	Relapsing-remitting Multiple Sclerosis	Drug: Interferon beta-1b	Claudio Gobbi	Bayer	Terminated	18 Years	70 Years	Both	5	Phase 4	Switzerland
5	EUCTR2010-023023-19-DE (EUCTR)	04/01/2012	18/11/2011	Studyto compare the efficacy and safety of fingolimod and interferon-beta-1bin patients with mutlipl ...	A 18-month, open-label, rater-blinded, randomized, multicenter, active-controlled, parallel-group pi ...	treating of cognitive symptoms in relapsing-remitting multiple sclerosis MedDRA version: 14.1;Level: ...	Trade Name: Gilenya Product Name: Fingolimod Product Code: FTY720 Other descriptive name: FINGOLIMOD HY ...	Novartis Farma S.p.A.	NULL	Not Recruiting			Female: yes Male: yes			Germany;Italy
6	EUCTR2010-023677-19-IT (EUCTR)	23/03/2011	10/06/2011	Bio-molecular effects of interferon-beta and d-vitamin association - VITAD-2010	Bio-molecular effects of interferon-beta and d-vitamin association - VITAD-2010	PATIENT WITH RRMS AND SPMS MedDRA version: 13.1;Level: HLT;Classification code 10052785;Term: Multip ...	Trade Name: BETAFERON15CONFEZ 0,25MG/ML+ INN or Proposed INN: Interferon beta-1b Trade Name: EXTAVIA ...	AZIENDA OSPEDALIERA S. LUIGI GONZAGA	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Italy
7	NCT01144052 (ClinicalTrials.gov)	June 2010	11/6/2010	Natalizumab De-escalation With Interferon Beta-1b	De-escalation After Natalizumab Treatment With Interferon-beta-1bin Patients With Relapsing-remittin ...	Relapsing-remitting Multiple Sclerosis	Drug: interferon beta-1b;Drug: Natalizumab	Claudio Gobbi	Ospedale Civico, Lugano	Completed	18 Years	60 Years	All	19	Phase 4	Switzerland
8	EUCTR2009-013284-19-AT (EUCTR)	10/12/2009	23/11/2009	Immune tolerance induction in MS patients with neutralizing antibodies against interferon-beta- HINA ...	Immune tolerance induction in MS patients with neutralizing antibodies against interferon-beta- HINA ...	multiple sclerosis patients with neutralizing antibodies against interferon-beta	Trade Name: Betaferon Other descriptive name: INTERFERON BETA-1B	Medical University Innsbruck	NULL	Not Recruiting			Female: yes Male: yes			Austria
9	NCT01339676 (ClinicalTrials.gov)	March 2008	19/4/2011	Colecalciferol as an Add-on Treatment to Interferon-beta-1b for Treatment of Multiple Sclerosis (MS)	Colecalciferol as an Add-on Treatment to Subcutaneously Administered Interferon-beta-1bfor Treatment ...	Multiple Sclerosis	Drug: Colecalciferol;Drug: Placebo capsules	University of Turku	NULL	Active, not recruiting	18 Years	55 Years	Both	70	Phase 4	Finland
10	NCT01432704 (ClinicalTrials.gov)	March 2008	16/8/2011	Colecalciferol as an Add-on Treatment to Subcutaneously-Administered Interferon-beta-1bfor Treatment ...	Phase IV Study of Colecalciferol as an Add-on Treatment to Subcutaneously Administered Interferon-be ...	Multiple Sclerosis	Drug: colecalciferol	University of Turku	Bayer	Completed	18 Years	50 Years	Both	70	Phase 2/Phase 3	NULL

First Previous1 2Next Last